

4 October 2021

## Neurology Pharma

### 1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- Aubagio (teriflunomide) 2
- Avonex (interferon beta-1a) 0
- Betaferon (interferon beta-1b) 0
- Brabio (glatiramer acetate) 0
- Copaxone (glatiramer acetate) 2
- Extavia (beta interferon-1b) 0
- Fampyra (fampridine) 0
- Gilenya (fingolimod) 1
- Lemtrada (alemtuzumab) 0
- Mavenclad (cladribine) 1
- Mayzent (siponimod) 0
- Ocrevus (ocrelizumab) 10
- Plegridy (peginterferon beta-1a) 0
- Rebif (beta interferon-1a) 0
- Tecfidera (dimethyl fumarate) 10
- Tysabri (natalizumab) 5
- Zeposia (ozanimod) 0

Response:

The information above relates to the patients with a diagnosis of multiple sclerosis. Unfortunately it is not possible to provide data which relates to any other neurological condition as this information is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

### 2. How many patients have been treated with the following drugs in the past 4 months:

- Aimovig (erenumab) - any disease
- Ajovy (fremanezumab) - any disease
- Emgality (galcanezumab) - any disease
- Botulinum Toxin (i.e. Botox, Dysport, Xeomin) – for migraine ONLY

Response:

**4 October 2021**

The information requested is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**3. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?**

Response:

Belfast Trust funds the use of Botulinum Toxin treatment for the treatment of Migraine. Belfast Trust has funded the use of monoclonal antibodies for the treatment of migraine.

**4. How many patients have been treated in the past 4 months for the following conditions:**

Response:

The information relating to chronic migraine is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

- Chronic migraine (15+ headache days per month)
- Episodic migraine (4-14 headache days per month)

The following information relates to Multiple Sclerosis:

- Relapsing remitting multiple sclerosis (RRMS) 295
- Primary progressive multiple sclerosis (PPMS) 40
- Secondary progressive multiple sclerosis (SPMS) 100